Clinical Trials Browser

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

Neoplasm Metastasis

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

Prostatic Neoplasms

Breast Neoplasms

Neoplasm Metastasis, Neoplasms, Recurrence

Prostatic Neoplasms

Paraganglioma, Pheochromocytoma

Small Cell Lung Carcinoma

Adenocarcinoma, Prostatic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Transitional Cell

Breast Neoplasms

Carcinoma, Squamous Cell

Breast Neoplasms

Endometrial Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Glioblastoma, Glioma

Breast Neoplasms, Triple Negative Breast Neoplasms

Prostatic Neoplasms

Advanced Breast Cancer

Breast Neoplasms

Neoplasm Metastasis

Premenopausal HR+/HER2- Metastatic Breast Cancer

Prostatic Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Hereditary Sensory and Autonomic Neuropathies

Triple Negative Breast Neoplasms

Colorectal Neoplasms

Breast Adenocarcinoma

Triple Negative Breast Neoplasms

Breast Neoplasms

Endometrial Neoplasms

ATM Gene Mutation

Prostate Cancer Metastatic

Breast Neoplasms

Ovarian Neoplasms

Clinical Trials

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

I-SPY

TAPUR

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

TRIO-US L-07

TALENT

TNBC

TALASUR

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

TAC-GReD

PERSEVERE

ZZ-First

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

FUTURE

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

Young-PALETTA

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

TARA

ROME

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

EVIDENT

Open-Label Extension and Safety Study of Talazoparib

Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer

Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

PANDA

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Telaglenastat + Talazoparib In Prostate Cancer

ABRAZO

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer